Cosmetic Safety Enhancement Act of 2019

General consumer protection issues. H.R. 5279 Personal Care Products Safety Act of 2019 H.R. 5141 Humane Cosmetics Act of 2019 S. 2886 Humane Cosmetics Act of 2019 S. 4626- SAFE Data Act of 2019

Client expense: $155,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to FDA regulation of cosmetics; Issues related to cosmetics and other personal care products; H.R. 5279 (116th Congress) - Cosmetic Safety Enhancement Act of 2019; Issues regarding implementation of the CARES Act (Public Law No: 116-136).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

General Consumer Protection issues. S. 726 Personal Care Products Safety Act H.R.5279 Cosmetic Safety Enhancement Act of 2019 H.R.5141 Humane Cosmetics Act of 2019 S.2886 Humane Cosmetics Act Executive Order on Addressing the Threat Posed by WeChat S.4626 - SAFE DATA Act

Client expense: $155,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Vice President of the U.S., White House Office

Legislation relating to chemical safety, cosmetic ingredients safety, and disclosure of fragrance ingredients in consumer products Formation of Congressional Fragrance Caucus S. 726 (Personal Care Products Safety Act), all provisions H.R. 5279 (Cosmetic Safety Enhancement Act of 2019), all provisions

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications -H.R.133 - Consolidated Appropriations Act, 2021, including legislation regarding average sales price (ASP) reporting requirements for certain hyaluronic acid (HA) products that are classified as devices, but reimbursed as drugs under Medicare Part B

Client expense: $1,450,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R. 5279, Cosmetic Safety Enhancement Act; H.R. 6058, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act of 2020; S. 3431/H.R. 7756, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; H.R. 5017, Natural Cosmetics Act; FDA Sunscreen Regulation

Client expense: $300,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)

H.R. 5668, the MODERN Labeling Act of 2020; H.R.5279, Cosmetic Safety Enhancement Act of 2019; S. 3872 and HR 7269, Promising Pathways Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to personal care product safety. Issues related to hazardous contaminants. H.R. 1816, Children's Product Warning Label Act of 2019. H.R.5279, Cosmetic Safety Enhancement Act of 2019. H.R.535, PFAS Action Act of 2019. H.R.2500/S. 1790 - National Defense Authorization Act for Fiscal Year 2020 H.R. 7197/S. 4012 RESTAURANTS Act of 2020.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation relating to chemical safety, cosmetic ingredient safety, and disclosure of fragrance ingredients in consumer products. Formation of Congressional Fragrance Caucus. S. 726 (Personal Care Products Safety Act), all provisions. H.R. 5279 (Cosmetic Safety Enhancement Act), all provisions. H.R. 5141/S. 2886 (Humane Cosmetics Act), all provisions. H.R. 5017 (Natural Cosmetics Act), all provisions.

Client expense: $80,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

consumer protection and cosmetic product safety, HR. 5279 and impact of law on Association members.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Consumer protection and cosmetic product safety, HR. 5279 and impact of law on Association members.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Consumer protection and cosmetic product safety, HR. 5279 and impact of law on Association members.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to FDA regulation of cosmetics; Issues related to cosmetics and other personal care products; H.R. 5279 - Cosmetic Safety Enhancement Act of 2019; Issues related to H.R. 748 - CARES Act (Public Law 116-136).

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1423, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 610, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 608, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education. H.R. 1430, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education S. 630, Arbitration Fairness for Consumers Act, a bill to amend the Consumer Financial Protection Act of 2010 with respect to arbitration. H.R. 1443, Ending Forced Arbitration of Sexual Harassment act of 2019, bill to amend title 9 of the United States Code with respect to arbitration, prohibiting the use of forced arbitration in cases of sexual harassment, assault, discrimination. S. 635, A bill to restore statutory rights to the people of the United States from forced arbitration. S. 620, Safety Over Arbitration, a bill to amend title 9, United States Code, with respect to arbitration. S. 726, Personal Care Products Safety Act, to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, specifically regarding preemption and immunity provisions. H.R. 2750, Justice for Servicemembers Act, prohibiting the use of forced arbitration against members of the armed forces. H.R. 2749/ S. 1491 Restoring Justice for Workers Act, prohibiting the use of forced arbitration in employment disputes. H.R. 3764, Justice for Student Borrowers Act, prohibiting the use of forced arbitration in student loan agreements. S. 766, PROTECT Asbestos Victims Act of 2019. H.R. 1603/ S. 717, Alan Reinstein Ban Asbestos Now Act of 2019. H.R. 1816, Children's Product Warning Label Act of 2019. Dingell and Cicilline amendments to H.R. 2500, National Defense Authorization Act, regarding PFAS CERCLA designation (Dingell), and prohibiting the use of forced arbitration in SCRA claims (Cicilline). H.R. 5216/ S. 2943, Quality Care for Nursing Home Residents Act of 2019. H.R. 5326, Fairness in Nursing Home Arbitration Act. H.R. 4544, Ensuring Fair Legal Recourse for Private Student Loan Borrowers Act. H.R. 5279, Cosmetic Safety Enhancement Act of 2019. H.R. 5017, Natural Cosmetics Act. H.R. 535, PFAS Action of 2019. S. 2838, A bill to amend the Ted Stevens Olympic Amateur Sports Act to improve transparency of the United States Center for Safe Sport, to provide grant accountability, and to protect victims of abuse from retaliation, and for other purposes. H.R. 4982, Health Care Workforce Protection Act of 2019. S. 3372, Health Care Workforce Protection Act. H.R. 748, CARES Act, with specific regard to immunity provisions. S. 3548, CARES Act, with specific regard to immunity provisions. H.R. 6201, Families First Coronavirus Response Act, with specific regard to immunity provisions. H.R. 6379, Take Responsibility for Workers and Families Act, with specific regard to immunity provisions. H.R. 6101/ S. 3400, Ending Passenger Rail Forced Arbitration. H.R. 6058, SHOP SAFE Act of 2020. H.R. 6044, Accurate Labels Act. H.R. 6395/ S. 4049, National Defense Authorization Act (NDAA), with specific regard to servicemember forced arbitration amendments. H.R. 7940, Protect America's Children from Toxic Pesticides Act. S. 4317, Safe to Work Act. S. 178, Delivering Immediate Relief to American Families, Schools, and Small Businesses Act. H.R. 7528, Get America Back to Work Act. H.R. 8237, Protecting the Employment Rights of Service Members. H.R. 133, Consolidated Appropriations Act, 2021. Portman/ Cornyn COVID Relief Draft Proposal. Draft Ending Mandatory Arbitration for Sexual Assault Claims Act. Draft legislation regarding additions to the PREP Act. General lobbying with regard to asbestos in talc and related liability issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to preemption of state causes of action. General lobbying with regard to PFAS liability issues. General lobbying with regard to evidence availability in pipeline safety legislation. General lobbying with regard to immunity provisions and liability frameworks in COVID-19 legislation. General lobbying with regard to nursing home COVID-19 liablity.

Client expense: $1,110,000 · Firm income: Not reported

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)

H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain HR 8837 -- Continuing Appropriations Act, 2021 and Other Extensions Act H.R.133 - Consolidated Appropriations Act, 2021

Client expense: $146,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.

Issues related to regulation of cosmetics industry and effect on small businesses; H.R.5279, Cosmetic Safety Enhancement Act of 2019.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Over the Counter Monograph and sunscreen provisions included in PL 116-136, Coronavirus Aid, Relief and Economic Security Act. H.R. 5279, Cosmetic Safety Enhancement Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pesticide Registration Improvement Act ingredient disclosure antimicrobials support of HR 5279 - Cosmetic Safety Enhancement act (encouraging FDA to define of naturals) Support of S726 _ Cosmetic Safety Enhancement act (encouraging FDA ti define naturals) House appopriations (support report language on Naturals encouraging FDA to define naturals)

Client expense: Not reported · Firm income: $12,500

S. 726, Personal Care Products Safety Act HR 5279, Cosmetic Safety Enhancement Act

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General Consumer Protection issues. S. 726 Personal Care Products Safety Act H.R.5279 Cosmetic Safety Enhancement Act of 2019 H.R.5141 Humane Cosmetics Act of 2019 S.2886 Humane Cosmetics Act Executive Order on Addressing the Threat Posed by WeChat

Client expense: $155,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Vice President of the U.S., White House Office

H.R. 5141/ S. 2886 - the Humane Cosmetics Act of 2019 - all provisions of the bill. H.R.1816 - Children's Product Warning Label Act of 2019 - a bill to require warning labels on talc-based cosmetics that could contain asbestos and are marketed to children. S. 726/H.R. The Personal Care Products Safety Act of 2019 - legislation related to the oversight and regulation of personal care products and cosmetics. H.R. 5279 - The Cosmetic Safety Enhancement Act of 2019 - legislation related to the oversight and regulation of personal care products and cosmetic

Client expense: $101,014 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation relating to chemical safety, cosmetic ingredients safety, and disclosure of fragrance ingredients in consumer products Formation of Congressional Fragrance Caucus S. 726 (Personal Care Products Safety Act), all provisions H.R. 5279 (Cosmetic Safety Enhancement Act of 2019), all provisions H.R. 5141 and S. 2886 (Humane Cosmetics Act of 2019), all provisions H.R. 5017 (Natural Cosmetics Act), all provisions

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES

Legislation relating to chemical safety, cosmetic ingredient safety, and disclosure of fragrance ingredients in consumer products. Formation of Congressional Fragrance Caucus. S. 726 (Personal Care Products Safety Act), all provisions. H.R. 5279 (Cosmetic Safety Enhancement Act), all provisions. H.R. 5141/S. 2886 (Humane Cosmetics Act), all provisions. H.R. 5017 (Natural Cosmetics Act), all provisions.

Client expense: $80,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

Cosmetics Reform Legislation (no bill number) Cosmetic Safety Enhancement Act of 2019 (H.R. 5279)

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Issues related to personal care product safety. Issues related to hazardous contaminants. H.R. 1816, Children's Product Warning Label Act of 2019. H.R.5279, Cosmetic Safety Enhancement Act of 2019. H.R.535, PFAS Action Act of 2019. H.R.2500/S. 1790 - National Defense Authorization Act for Fiscal Year 2020 H.R. 7197, RESTAURANTS Act of 2020.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Consumer protection and cosmetic product safety, HR. 5279 and impact of law on Association members.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Consumer protection and cosmetic product safety, HR. 5279 and impact of law on Association members.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

consumer protection and cosmetic product safety, HR. 5279 and impact of law on Association members.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1423, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 610, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 608, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education. H.R. 1430, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education S. 630, Arbitration Fairness for Consumers Act, a bill to amend the Consumer Financial Protection Act of 2010 with respect to arbitration. H.R. 1443, Ending Forced Arbitration of Sexual Harassment act of 2019, bill to amend title 9 of the United States Code with respect to arbitration, prohibiting the use of forced arbitration in cases of sexual harassment, assault, discrimination. S. 635, A bill to restore statutory rights to the people of the United States from forced arbitration. S. 620, Safety Over Arbitration, a bill to amend title 9, United States Code, with respect to arbitration. S. 726, Personal Care Products Safety Act, to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, specifically regarding preemption and immunity provisions. H.R. 2750, Justice for Servicemembers Act, prohibiting the use of forced arbitration against members of the armed forces. H.R. 2749/ S. 1491 Restoring Justice for Workers Act, prohibiting the use of forced arbitration in employment disputes. H.R. 3764, Justice for Student Borrowers Act, prohibiting the use of forced arbitration in student loan agreements. S. 766, PROTECT Asbestos Victims Act of 2019. H.R. 1603/ S. 717, Alan Reinstein Ban Asbestos Now Act of 2019. H.R. 1816, Children's Product Warning Label Act of 2019. Dingell and Cicilline amendments to H.R. 2500, National Defense Authorization Act, regarding PFAS CERCLA designation (Dingell), and prohibiting the use of forced arbitration in SCRA claims (Cicilline). H.R. 5216/ S. 2943, Quality Care for Nursing Home Residents Act of 2019. H.R. 5326, Fairness in Nursing Home Arbitration Act. H.R. 4544, Ensuring Fair Legal Recourse for Private Student Loan Borrowers Act. H.R. 5279, Cosmetic Safety Enhancement Act of 2019. H.R. 5017, Natural Cosmetics Act. H.R. 535, PFAS Action of 2019. S. 2838, A bill to amend the Ted Stevens Olympic Amateur Sports Act to improve transparency of the United States Center for Safe Sport, to provide grant accountability, and to protect victims of abuse from retaliation, and for other purposes. H.R. 4982, Health Care Workforce Protection Act of 2019. S. 3372, Health Care Workforce Protection Act. H.R. 748, CARES Act, with specific regard to immunity provisions. S. 3548, CARES Act, with specific regard to immunity provisions. H.R. 6201, Families First Coronavirus Response Act, with specific regard to immunity provisions. H.R. 6379, Take Responsibility for Workers and Families Act, with specific regard to immunity provisions. H.R. 6101/ S. 3400, Ending Passenger Rail Forced Arbitration. H.R. 6058, SHOP SAFE Act of 2020. H.R. 6044, Accurate Labels Act. H.R. 6395/ S. 4049, National Defense Authorization Act (NDAA), with specific regard to servicemember forced arbitration amendments. H.R. 7940, Protect America's Children from Toxic Pesticides Act. S. 4317, Safe to Work Act. S. 178, Delivering Immediate Relief to American Families, Schools, and Small Businesses Act. H.R. 7528, Get America Back to Work Act. H.R. 8237, Protecting the Employment Rights of Service Members. Draft Ending Mandatory Arbitration for Sexual Assault Claims Act. Draft legislation regarding additions to the PREP Act. General lobbying with regard to asbestos in talc and related liability issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to preemption of state causes of action. General lobbying with regard to PFAS liability issues. General lobbying with regard to evidence availability in pipeline safety legislation. General lobbying with regard to immunity provisions in COVID-19 legislation. General lobbying with regard to nursing home COVID-19 liablity.

Client expense: $1,400,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)

- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications

Client expense: $860,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Issues related to FDA regulation of cosmetics; Issues related to cosmetics and other personal care products; H.R. 5279 - Cosmetic Safety Enhancement Act of 2019; Issues related to H.R. 748 - CARES Act (Public Law 116-136).

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Humane Cosmetics Act (H.R. 5141/S. 2886), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279). The FDA's proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Section 213 of S.1895, the Lower Health Care Cost Act, related to modernizing the labeling of certain generic drugs; H.R. 5668, the MODERN Labeling Act of 2020; H.R.5279, Cosmetic Safety Enhancement Act of 2019; S. 3872 and HR 7269, Promising Pathways Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to regulation of cosmetics industry and effect on small businesses; H.R.5279, Cosmetic Safety Enhancement Act of 2019.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1816, Children's Product Warning Label Act of 2019; H.R. 5279, Cosmetic Safety Enhancement Act; H.R. 5141/S. 2886, Humane Cosmetics Act - Issues related to regulation of cosmetic animal testing; H.R. 6058, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act of 2020; S. 3431/H.R. 7756, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; H.R. 5017, Natural Cosmetics Act; H.R. 5986/S. 4401, Environmental Justice For All Act; FDA Sunscreen Regulation

Client expense: $350,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)

OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 726), Cosmetic Safety Enhancement Act of 2019 (H.R. 5279), Children's Products Warning Label Act of 2019 (H.R. 1816)

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain HR 8837 -- Continuing Appropriations Act, 2021 and Other Extensions Act

Client expense: $140,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.

Implementation of the Over the Counter Monograph and sunscreen provisions included in PL 116-136, Coronavirus Aid, Relief and Economic Security Act. H.R. 5279, Cosmetic Safety Enhancement Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE